Per Malmström
121 – 130 of 158
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2000
-
Mark
Predictive value of p53, mdm-2, p21, and mib-1 for chemotherapy response in advanced breast cancer
(
- Contribution to journal › Article
-
Mark
Quality of life in patients with metastatic breast cancer receiving either docetaxel or sequential methotrexate and 5-fluorouracil. A multicentre randomised phase III trial by the Scandinavian breast group
(
- Contribution to journal › Article
-
Mark
ErbB2 status and the benefit from two or five years of adjuvant tamoxifen in postmenopausal early stage breast cancer
2000) In Annals of oncology : official journal of the European Society for Medical Oncology 11(12). p.1545-1550(
- Contribution to journal › Article
- 1999
-
Mark
Vascular endothelial growth factor (VEGF) and urokinase plasminogen activator (uPA) are independent prognostic factors for distant recurrence in premenopausal node-negative breast cancer
(
- Contribution to journal › Published meeting abstract
-
Mark
Predictive value of P53, MDM-2, P21-expression, KI-67 for response to docetaxel or methotrexate-fluorouracil (MF) in advanced breast cancer
(
- Contribution to journal › Published meeting abstract
-
Mark
Predictive value c-erB-B2 expression for response to docetaxel (D) or methotrexate-fluorouracil (MF) in advanced breast cancer
(
- Contribution to journal › Published meeting abstract
- 1998
-
Mark
Urokinase plasminogen activator and flow cytometric S-phase fraction as prognostic indicators in breast cancer
(
- Contribution to journal › Published meeting abstract
-
Mark
A dose intensity study of epirubicin weekly for disseminated breast cancer
(
- Contribution to journal › Published meeting abstract
-
Mark
Dosage of adjuvant G-CSF (filgrastim)-supported FEC polychemotherapy based on equivalent haematological toxicity in high-risk breast cancer patients. Scandinavian Breast Group, Study SBG 9401
1998) In Annals of oncology : official journal of the European Society for Medical Oncology 9(4). p.403-411(
- Contribution to journal › Article
-
Mark
Dacarbazine-vindesine versus dacarbazine-vindesine-cisplatin in disseminated malignant melanoma. A randomised phase III trial
(
- Contribution to journal › Article